Drug intelligence / Profile preview

ESG206

Development stage: Phase 2
Lead developer: Shanghai Escugen Biotechnology
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Intravenous

Overview

ESG206 is a recombinant humanized monoclonal antibody targeting the B-cell activating factor receptor (BAFFR; also known as tumor necrosis factor receptor superfamily member 13C or TNFRSF13C). It has been glycoengineered to enhance antibody-dependent cellular cytotoxicity (ADCC) effects. The drug is being developed primarily for the treatment of relapsed or refractory B-cell malignancies, including cases resistant to CD19 or CD20-targeted therapies such as rituximab and ibrutinib. Preclinical studies have demonstrated antitumor activity in various malignant B cell disease models. Clinical development includes phase I/II trials for indications such as B-cell lymphoma and idiopathic thrombocytopenic purpura[1][2][3][4].

Other names: anti-BAFFR monoclonal antibody ESG206

Targets

TNFRSF13C (B-cell Activating Factor Receptor)

Beyond the preview

Go deeper on ESG206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ESG206.

Explore the full profile